Background: In preclinical research, tumor growth inhibition in subcutaneous models is frequently employed to evaluate therapeutic efficacy; however, such models often lack clinical translatability.
Methods: To better approximate clinical reality, taking the case of doxorubicin treatment, we utilized an orthotopic transplant and resection (OtR) strategy to systematically assess the effects of neoadjuvant chemotherapy, adjuvant chemotherapy, and their combination on tumor growth, recurrence, and malignant progression.
Results: Surprisingly, none of the treatments improved mouse survival, with adjuvant therapy even shortening it. Although neoadjuvant chemotherapy delayed preoperative tumor growth, and all regimens reduced recurrence rates, none effectively prevented metastasis. Furthermore, all treatment groups exhibited weight loss, indicative of chemotherapy-induced cachexia.
Conclusions: Collectively, these findings demonstrate that reduced tumor growth in preclinical mouse models does not necessarily translate into overall survival benefit. Our results emphasize the critical importance of prioritizing metastasis prevention over tumor growth inhibition as a key efficacy endpoint in antitumor drug evaluation.
| [1] |
Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022; 12(7): 3049-3062.
|
| [2] |
Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019; 18(7): 495-496.
|
| [3] |
Liu ITT, Kesselheim AS, Cliff ERS. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval. JAMA. 2024; 331(17): 1471-1479.
|
| [4] |
Ferrer M, Anthony TG, Ayres JS, et al. Cachexia: A systemic consequence of progressive, unresolved disease. Cell. 2023; 186(9): 1824-1845.
|
| [5] |
Su J x, Li S j, Zhou X f, et al. Chemotherapy-induced metastasis: molecular mechanisms and clinical therapies. Acta Pharmacol Sin. 2023; 44(9): 1725-1736.
|
| [6] |
Karagiannis GS, Condeelis JS, Oktay MH. Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions. Cancer Res. 2019; 79(18): 4567-4576.
|
| [7] |
Shaked Y. The pro-tumorigenic host response to cancer therapies. Nat Rev Cancer. 2019; 19(12): 667-685.
|
| [8] |
Deo A, Sleeman JP, Shaked Y. The role of host response to chemotherapy: resistance, metastasis and clinical implications. Clin Exp Metastasis. 2024; 41(4): 495-507.
|
| [9] |
Karagiannis GS, Condeelis JS, Oktay MH. Chemotherapy-induced metastasis: mechanisms and translational opportunities. Clin Exp Metastasis. 2018; 35(4): 269-284.
|
| [10] |
Hirmas N, Holtschmidt J, Loibl S. Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer. Cancers (Basel). 2024; 16(18):3236.
|
| [11] |
Li X, Luo L, Qian H. Improving the predictive accuracy of efficacy evaluation using tumor orthotopic transplant and resection model. Front Pharmacol. 2024; 15:1309876.
|
| [12] |
Hu J, Sánchez-Rivera FJ, Wang Z, et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature. 2023; 616(7958): 806-813.
|
| [13] |
Nobre AR, Dalla E, Yang J, et al. ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung. Nat Cancer. 2022; 3(10): 1165-1180.
|
| [14] |
Di Martino JS, Nobre AR, Mondal C, et al. A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy. Nat Cancer. 2022; 3(1): 90-107.
|
| [15] |
He D, Wu Q, Tian P, et al. Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps. Cancer Cell. 2025; 43:S1535-6108(25)00257–0.
|
| [16] |
Carlson P, Dasgupta A, Grzelak CA, et al. Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Nat Cell Biol. 2019; 21(2): 238-250.
|
| [17] |
Keklikoglou I, Cianciaruso C, Güç E, et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol. 2019; 21(2): 190-202.
|
| [18] |
Naumov GN, Townson JL, MacDonald IC, et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat. 2003; 82(3): 199-206.
|
| [19] |
Haykal T, Yang R, Tohme C, et al. Surgery-induced neutrophil extracellular traps promote tumor metastasis by reprogramming cancer cell lipid metabolism. Cancer Res. 2025. Online ahead of print.
|
| [20] |
Swanton C, Bernard E, Abbosh C, et al. Embracing cancer complexity: hallmarks of systemic disease. Cell. 2024; 187(7): 1589-1616.
|
| [21] |
Boire A, Burke K, Cox TR, et al. Why do patients with cancer die? Nat Rev Cancer. 2024; 24(8): 578-589.
|
| [22] |
Lyden D, Ghajar CM, Correia AL, et al. Metastasis. Cancer Cell. 2022; 40(8): 787-791.
|
RIGHTS & PERMISSIONS
2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
PDF
(6397KB)
